Morgan Stanley boosted its position in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 11.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 273,724 shares of the biotechnology company’s stock after buying an additional 28,069 shares during the period. Morgan Stanley owned about 0.40% of Momenta Pharmaceuticals worth $3,655,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of MNTA. FMR LLC increased its position in shares of Momenta Pharmaceuticals by 0.9% in the first quarter. FMR LLC now owns 10,773,450 shares of the biotechnology company’s stock worth $143,826,000 after buying an additional 93,702 shares during the period. Vanguard Group Inc. increased its position in shares of Momenta Pharmaceuticals by 3.4% in the first quarter. Vanguard Group Inc. now owns 5,953,677 shares of the biotechnology company’s stock worth $79,481,000 after buying an additional 195,996 shares during the period. Bank of New York Mellon Corp increased its position in shares of Momenta Pharmaceuticals by 4.3% in the first quarter. Bank of New York Mellon Corp now owns 793,735 shares of the biotechnology company’s stock worth $10,596,000 after buying an additional 32,760 shares during the period. JPMorgan Chase & Co. increased its position in shares of Momenta Pharmaceuticals by 65.1% in the first quarter. JPMorgan Chase & Co. now owns 636,744 shares of the biotechnology company’s stock worth $8,500,000 after buying an additional 251,159 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Momenta Pharmaceuticals by 10.5% in the first quarter. Geode Capital Management LLC now owns 528,877 shares of the biotechnology company’s stock worth $7,059,000 after buying an additional 50,289 shares during the period. Hedge funds and other institutional investors own 87.15% of the company’s stock.

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) traded down 3.44% during mid-day trading on Thursday, hitting $15.45. 131,748 shares of the stock traded hands. The company has a 50-day moving average of $16.64 and a 200 day moving average of $15.72. The firm’s market capitalization is $1.14 billion. Momenta Pharmaceuticals, Inc. has a 1-year low of $10.66 and a 1-year high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.50). The business had revenue of $23.57 million for the quarter, compared to analysts’ expectations of $24.64 million. Momenta Pharmaceuticals had a negative return on equity of 12.28% and a negative net margin of 39.35%. The business’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same period last year, the firm posted ($0.31) earnings per share. On average, equities research analysts anticipate that Momenta Pharmaceuticals, Inc. will post ($1.16) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Momenta Pharmaceuticals, Inc. (MNTA) Stake Boosted by Morgan Stanley” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/08/17/momenta-pharmaceuticals-inc-mnta-stake-boosted-by-morgan-stanley.html.

A number of research analysts have recently issued reports on MNTA shares. Stifel Nicolaus restated a “buy” rating and issued a $26.00 price target on shares of Momenta Pharmaceuticals in a research report on Thursday, August 3rd. BidaskClub downgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, July 6th. Aegis restated a “hold” rating and issued a $17.00 price target on shares of Momenta Pharmaceuticals in a research report on Wednesday, May 3rd. Barclays PLC downgraded shares of Momenta Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $20.00 to $17.00 in a research report on Monday, May 22nd. Finally, Cowen and Company restated a “hold” rating and issued a $15.00 price target on shares of Momenta Pharmaceuticals in a research report on Wednesday, May 3rd. Two analysts have rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the stock. Momenta Pharmaceuticals presently has an average rating of “Hold” and an average target price of $16.63.

In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 4,116 shares of the firm’s stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $15.83, for a total value of $65,156.28. Following the transaction, the president now directly owns 281,919 shares of the company’s stock, valued at $4,462,777.77. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 23,686 shares of company stock worth $393,741 over the last three months. Insiders own 4.40% of the company’s stock.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Stock Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.